Lu Alleruzzo
Fondatore presso Immunophotonics, Inc.
Posizioni attive di Lu Alleruzzo
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Immunophotonics, Inc.
 Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Direttore/Membro del Consiglio | 01/01/2009 | - |
| Amministratore Delegato | - | - | |
| Fondatore | 01/01/2009 | - | |
| Direttore operativo | 01/01/2009 | - | |
| Presidente | 01/01/2009 | - |
Storia della carriera di Lu Alleruzzo
Formazione di Lu Alleruzzo
| University of Missouri | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
Posizioni
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| Chief Operating Officer | 1 |
Settori
| Health Technology | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Health Technology |
- Borsa valori
- Insiders
- Lu Alleruzzo
- Esperienza
